FIGURE 1
mIDH1-U87 vascular endothelial growth factor (VEGF) secretion and cell viability. (A) VEGF secretion ofmIDH1-U87 cells was assessed with immunoassay (B) Cell viability (%) of mIDH1-U87 cell lines after 72 h bevacizumab treatment at different cell line viability. Concentrations (0.1 mg/mL to 1 mg/mL) was assessed with the MTT assay. Bevacizumab has no significant effect (p > 0.05) on mIDH1-U87 cell line viability.
FIGURE 2
(A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. 1H CPMG spectrum of cells incubated with bevacizumab (D, RED).
TABLE 1
Principal discriminant metabolites. An up arrow (↑) ↓↓ corresponds to an increase of the concentration induced by bevacizumab
| Peak number | Chemical shift (ppm) | Attributions | Concentration variations Induced by Bev | |
|---|---|---|---|---|
| 1 | 184/2.24/3 | 2OH-glutarate | ↑ | 20% |
| 2 | 3.22 | GPC/chol | ↑ | 9% |
| 3 | 2.11/2.34/2.55/3 02 | glutamate | ↑ | 25% |
| 4 | 1.475 | alanine | ↑ | 25% |
| 5 | 0.88 | (CH2)n-CH3 | ↑ | 32% |
| 6 | 1.28 | (CH 2)n-CH2-(CH2)m | ↑ | 20% |
| 7 | 2.95 | creatine | ↑ | 15% |
| 8 | 3.02 | creatine | ↑ | 25% |
| 9 | 3.2 | Pcholine | ↑ | 7% |
| 10 | 3.3-3.42 | Taurine | ↑ | 30% |
| 11 | 3.6 | glycine | ↑ | ND |
| 12 | 3.65-3.71 | GPC | ↑ | 35% |
[i] Bev = bevacizumab; GPC = glycerophosphocholine; ND = not determined; Pcholine = phosphocholine